Qyuns Therapeutics to Acquire Remaining 34% Stake in CMC Subsidiary Cellularforce for RMB 86M – Full Ownership Secures NDA Pathway for IL-17A and IL-4Rα Antibody Pipeline
Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine...